Abstract
The clinical success of gene therapy is critically dependent on the development of efficient and safe gene delivery reagents, popularly known as “Transfection Vectors”. The transfection vectors commonly used in gene therapy are mainly of two types: viral and non-viral. The efficiencies of viral transfection vectors are, in general, superior to their non-viral counterparts. However, the myriads of potentially adverse immunogenic aftermaths associated with the use of viral vectors are increasingly making the non-viral gene delivery reagents as the vectors of choice. Among the existing arsenal of non-viral gene delivery reagents, the distinct advantanges associated with the use of cationic transfection lipids include their: (a) robust manufacture; (b) ease in handling & preparation techniques; (c) ability to inject large lipid:DNA complexes and (d) low immunogenic response. The present review will highlight the successes, set-backs, challenges and future promises of cationic transfection lipids in non-viral gene therapy.
Keywords: cationic lipids, gene therapy, targeted gene delivery, systemic delivery, lipoplexes
Current Medicinal Chemistry
Title: Cationic Transfection Lipids in Gene Therapy: Successes, Set-backs, Challenges and Promises
Volume: 10 Issue: 14
Author(s): Valluripalli Vinod Kumar, Rajkumar Sunil Singh and Arabinda Chaudhuri
Affiliation:
Keywords: cationic lipids, gene therapy, targeted gene delivery, systemic delivery, lipoplexes
Abstract: The clinical success of gene therapy is critically dependent on the development of efficient and safe gene delivery reagents, popularly known as “Transfection Vectors”. The transfection vectors commonly used in gene therapy are mainly of two types: viral and non-viral. The efficiencies of viral transfection vectors are, in general, superior to their non-viral counterparts. However, the myriads of potentially adverse immunogenic aftermaths associated with the use of viral vectors are increasingly making the non-viral gene delivery reagents as the vectors of choice. Among the existing arsenal of non-viral gene delivery reagents, the distinct advantanges associated with the use of cationic transfection lipids include their: (a) robust manufacture; (b) ease in handling & preparation techniques; (c) ability to inject large lipid:DNA complexes and (d) low immunogenic response. The present review will highlight the successes, set-backs, challenges and future promises of cationic transfection lipids in non-viral gene therapy.
Export Options
About this article
Cite this article as:
Kumar Vinod Valluripalli, Singh Sunil Rajkumar and Chaudhuri Arabinda, Cationic Transfection Lipids in Gene Therapy: Successes, Set-backs, Challenges and Promises, Current Medicinal Chemistry 2003; 10 (14) . https://dx.doi.org/10.2174/0929867033457458
DOI https://dx.doi.org/10.2174/0929867033457458 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Models of Antigen Receptor Activation in the Design of Vaccines
Current Pharmaceutical Design Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry SnoN: Bridging Neurobiology and Cancer Biology
Current Molecular Medicine Editorial (Thematic Issue: Cell Therapy and Regenerative Medicine)
Current Molecular Pharmacology Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology Platforms in Diagnosis and Treatment of Primary Brain Tumors
Recent Patents on Nanotechnology Recent Patents for Predictive and Prognostic Biomarkers in Non-Small-Cell Lung Cancer
Recent Patents on Biomarkers NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design Defensins and Other Biocidal Proteins from Bean Seeds with Medicinal Activities
Current Medicinal Chemistry Modification of Alternative Splicing by Antisense Oligonucleotides as a Potential Chemotherapy for Cancer and Other Diseases
Current Cancer Drug Targets Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research A Stack Autoencoders Based Deep Neural Network Approach for Cervical Cell Classification in Pap-Smear Images
Recent Advances in Computer Science and Communications Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction
Anti-Cancer Agents in Medicinal Chemistry Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry An In Silico Immunogenicity Analysis for PbHRH: An Antiangiogenic Peptibody by Fusing HRH Peptide and Human IgG1 Fc Fragment
Current Bioinformatics Drug Resistance in Melanoma: New Perspectives
Current Medicinal Chemistry